God  our Guide  One Nation under God







Natural Makeup
Neck Pain
Ocular Female diseases
Chronic fatigue syndrome

Learn  about Brain

Fixall diseases
Memory problems
Breast Lymph Drainage
Kidney stone Buster
Bras cause breast cancer
Skin repair Clinic

Myofacial pain

Lower back pain

Disc herniation

Back pain

Neck pain tips

Are You Hypothyroid

Vitamin-D Deficiency

Dubai Trip

Deodorants Breast Cancer

 women getting strokes

Mammograms Cancer

Learning disability


How to reduce stress


Stress  Homeopathy

Anemia &celiac disease

Autonomic Small Fiber

Fix for ITP 

Migraine in celaic


 More diseases


Self attack


Health Foods

Vaginal discharge

 Alopecia treatment

  Nail Fungus


   Nerve disorder diagnosis in Autoimmune diseases



C.I.D.P  ALS Diagnosis

 e.book the flame within  

Many patients with CIDP , MMF, LSS , SFN can easily be treated early on , but their diagnosis is missed and the disease progresses and may turn into ALS. Once in advanced stage of disease there is no turning back. CIDPUSA provides a few studies to help get early diagnosis and certainly contact us for guidance.

Return to Neurological Variants of celiac disease


 2006 Mar;8(2):91-103. 

Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy.

De Sousa EA,

Department of Neurology, Weill Medical College of Cornell University, 635 Madison Avenue, Suite 400, New York, NY 10022, USA.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated acquired polyneuropathy that may lead to disability. CIDP is characterized by an autoimmune attack against peripheral nervous system myelin, by cellular and humoral mechanisms. Early diagnosis and treatment may yield better functional recovery, probably by minimizing secondary axonal loss from a primary demyelinating insult. Intravenous immunoglobulin and plasmapheresis are considered standard-of-care therapy in CIDP, based on randomized, double-blinded, placebo-controlled evidence. Corticosteroids, despite less robust evidence, are also considered standard therapy for CIDP. Other nonstandard therapies may work in refractory patients. These include azathioprine, cyclophosphamide, cyclosporine A, etanercept, interferon-alpha 2a, mycophenolate mofetil, and tacrolimus. Emerging therapies include interferon-beta 1a, rituximab, and high-dose cyclophosphamide without stem-cell rescue. Because most patients will require prolonged therapy, long-term side effects are important considerations.

PMID: 16464406 [PubMed]

Rinsho Shinkeigaku. 2001 Dec;41(12):1210-3.
[New trends in neuropathy practice: clinical approach to CIDP].
Baba M.

Department of Neurological Sciences, Hirosaki University School of Medicine.

Our recent study showed that the overall prevalence of CIDP was estimated as 2.2 per 100,000 population in Aomori Prefecture, in Northan Honshu of Japan. In our series of more than 80 cases with CIDP, a chronic acquired inflammatory demyelinating polyneuropathy, nearly 30% showed clear laterality of weakness, and electrophysiologic laterality or multifocality was apparent in almost all cases. Nearly 90% of patients were able to walk without walking aids or other assistance. Sixty% showed distal dominant muscular weakness. In 12 patients with age of onset under 15, pes cavus deformity was seen in 5. Two thirds complained numbness in the extremities during progressive phase. Four cases initially showed severe sensory ataxia associated with motor conduction block. It should be, thus, reminded that clinical spectrum of CIDP is enormously wide: chronic acquired demyelinating multiple mononeuropathy showing asymmetric involvement (Lewis-Summer syndrome) should be put on one side of the clinical presentation of CIDP. Multifocal motor neuropathy (MMN) is, on the other hand, an unique syndrome mimicking amyotrophic lateral sclerosis (ALS). There may be, however, true association syndrome of CIDP and ALS presenting both peripheral nerve demyelination and pyramidal sign with progressive bulbar involvement. Recently, several atypical varieties of CIDP showing only one-limb involvement, upper limb weakness rather than lower limb power loss, or proximal weakness, etc ... have been reported in the literature. To realize such clinical variations of chronic acquired demyelinating neuropathy is important for early diagnosis and commencement of treatment of CIDP. Clinical guideline for suspicion of CIDP could be useful for general physicians and neurologists unfamiliar to peripheral neuropathies.



Please continue to the Migraine caused by celiac disease


Next Topic: